10758488

Cases: 3
Active: 0; 3 closed
Filed: 2021–2022
Top venue: D. Delaware; 2 cases

Jazz Pharmaceuticals, Inc. et al. v. Avadel CNS Pharmaceuticals, LLC

consolidated; '963 claims dismissed; other patents proceeded

Docket:: 1:21-cv-00691-GBW
Court:: U.S. District Court for the District of Delaware
Filed:: 2021-05-12

Patents:8731963 10758488 11147782

π Jazz Pharmaceuticals, Inc.π Jazz Pharmaceuticals Ireland Limited Δ Avadel CNS Pharmaceuticals, LLC

First Jazz Complaint in D. Del. over Avadel's FT218/LUMRYZ. The consolidated action asserted five patents, including U.S. 8,731,963. The court held the '963 claims directed to systems, not methods, and ordered Jazz to request delisting from the Orange Book; on March 7, 2023, the '963 infringement claims and related counterclaims were dismissed by stipulation. Other patents, including U.S. 10,758,488 and 11,147,782, proceeded to a 2024 jury verdict.

Avadel CNS Pharmaceuticals, LLC et al. v. Jazz Pharmaceuticals, Inc. et al.

dismissed with prejudice (settled)

Docket:: 1:22-cv-00487-GBW
Court:: U.S. District Court for the District of Delaware
Filed:: 2022-04-14
Terminated:: 2025-10-27

Patents:10758488

π Avadel CNS Pharmaceuticals, LLC π Avadel Pharmaceuticals plc Δ Jazz Pharmaceuticals, Inc.Δ Jazz Pharmaceuticals Ireland Ltd.

Avadel's action against Jazz alleging breach of confidentiality agreements, trade-secret misappropriation, correction of inventorship under 35 U.S.C. § 256, and antitrust counterclaims, relating to subject matter Avadel alleges Jazz copied into its patents including the '488 patent. Jazz's motion to dismiss and motions to stay were denied. Resolved by the October 2025 global settlement and dismissed with prejudice.

Untitled case

reversed/vacated in part

Docket:: 24-2274
Court:: U.S. Court of Appeals for the Federal Circuit
Terminated:: 2025-05-06

Patents:10758488 11147782

Appeal arising from the February 2024 patent trial/injunction phase after the March 4, 2024 verdict. The Federal Circuit issued an opinion on May 6, 2025 reversing/vacating portions of the district court's injunction relating to open-label extensions, new clinical trials, and seeking FDA approval for additional indications. The narrative could not confirm whether any ruling on the '488 patent itself was appealed.